MX2023002507A - Inhibidores de cd73. - Google Patents

Inhibidores de cd73.

Info

Publication number
MX2023002507A
MX2023002507A MX2023002507A MX2023002507A MX2023002507A MX 2023002507 A MX2023002507 A MX 2023002507A MX 2023002507 A MX2023002507 A MX 2023002507A MX 2023002507 A MX2023002507 A MX 2023002507A MX 2023002507 A MX2023002507 A MX 2023002507A
Authority
MX
Mexico
Prior art keywords
inhibitors
compounds
compositions
infections
cancer
Prior art date
Application number
MX2023002507A
Other languages
English (en)
Inventor
John Eksterowicz
Daqing Sun
Liusheng Zhu
Hiroyuki Kawai
Xiaohui Du
Yosup Rew
Valeria R Fantin
Brian R Blank
Jared Moore
Qiuping Ye
Tatiana Zavorotinskaya
Kejia Wu
Johnny Pham
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of MX2023002507A publication Critical patent/MX2023002507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals

Abstract

En la presente se describen inhibidores de CD73 y las composiciones farmacéuticas que comprenden estos compuestos. Los compuestos y composiciones de la invención son útiles para el tratamiento de cáncer, infecciones y enfermedades neurodegenerativas.
MX2023002507A 2018-04-30 2020-10-29 Inhibidores de cd73. MX2023002507A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862664841P 2018-04-30 2018-04-30
US201862737647P 2018-09-27 2018-09-27
US201862757714P 2018-11-08 2018-11-08
US201862777697P 2018-12-10 2018-12-10
US201962810790P 2019-02-26 2019-02-26

Publications (1)

Publication Number Publication Date
MX2023002507A true MX2023002507A (es) 2023-03-13

Family

ID=68386646

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011542A MX2020011542A (es) 2018-04-30 2019-04-30 Inhibidores de cd73.
MX2023002507A MX2023002507A (es) 2018-04-30 2020-10-29 Inhibidores de cd73.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020011542A MX2020011542A (es) 2018-04-30 2019-04-30 Inhibidores de cd73.

Country Status (13)

Country Link
US (3) US11325938B2 (es)
EP (1) EP3787635A4 (es)
JP (1) JP2021522280A (es)
KR (1) KR20210018255A (es)
CN (1) CN112423764A (es)
AU (1) AU2019261976A1 (es)
BR (1) BR112020022068A2 (es)
CA (1) CA3098493A1 (es)
IL (1) IL304348B1 (es)
MX (2) MX2020011542A (es)
SG (1) SG11202010790XA (es)
TW (1) TW202014182A (es)
WO (1) WO2019213174A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
MX2020011542A (es) 2018-04-30 2020-11-24 Oric Pharmaceuticals Inc Inhibidores de cd73.
WO2019232319A1 (en) * 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
MX2020013320A (es) * 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
CA3134613A1 (en) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Compounds targeting prmt5
KR102653726B1 (ko) * 2019-10-30 2024-04-01 오릭 파마슈티칼스, 인크. Cd73 억제제
CN117642411A (zh) 2021-05-11 2024-03-01 西藏海思科制药有限公司 小分子cd73拮抗剂及其用途
CN116217644B (zh) * 2023-04-24 2023-08-08 南京颐媛生物医学研究院有限公司 抗冠状病毒核糖核苷类化合物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477454A1 (en) * 1990-09-28 1992-04-01 Merrell Dow Pharmaceuticals Inc. Novel phosphonate derivatives of certain nucleosides
AU2002232660A1 (en) 2000-12-15 2002-06-24 Pharmasset Ltd. Antiviral agents for treatment of flaviviridae infections
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US20090029949A1 (en) 2006-05-25 2009-01-29 Parrill-Baker Abby L GPCR Ligands Identified by Computational Modeling
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
US20090274686A1 (en) * 2008-05-02 2009-11-05 Yat Sun Or Nucleoside phosphonate derivatives
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
ES2963759T3 (es) * 2016-01-08 2024-04-01 Arcus Biosciences Inc Moduladores de la 5'-nucleotidasa, ecto y su uso
CN110234656B (zh) * 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
US11058704B2 (en) * 2016-10-03 2021-07-13 Arcus Biosciences, Inc. Inhibitors of adenosine 5′-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
CN110402249A (zh) 2016-12-22 2019-11-01 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
US20200115404A1 (en) * 2017-03-31 2020-04-16 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
WO2019090111A1 (en) 2017-11-03 2019-05-09 Oric Pharmaceuticals, Inc. Cd73 inhibitors
MX2020011542A (es) 2018-04-30 2020-11-24 Oric Pharmaceuticals Inc Inhibidores de cd73.
WO2019232319A1 (en) 2018-05-31 2019-12-05 Peloton Therapeutics, Inc. Compositions and methods for inhibiting cd73
MX2020013320A (es) 2018-06-21 2021-02-22 Calithera Biosciences Inc Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
WO2020046813A1 (en) 2018-08-27 2020-03-05 Arcus Biosciences, Inc. Cd73 inhibitors
WO2020257429A1 (en) 2019-06-20 2020-12-24 Calithera Biosciences, Inc. Ectonucleotidase inhibitors and methods of use thereof
EP3999517A4 (en) 2019-07-16 2023-07-12 Oric Pharmaceuticals, Inc. CD73 INHIBITORS
KR102653726B1 (ko) 2019-10-30 2024-04-01 오릭 파마슈티칼스, 인크. Cd73 억제제

Also Published As

Publication number Publication date
TW202014182A (zh) 2020-04-16
US11325938B2 (en) 2022-05-10
IL304348B1 (en) 2024-04-01
CA3098493A1 (en) 2019-11-07
EP3787635A1 (en) 2021-03-10
JP2021522280A (ja) 2021-08-30
WO2019213174A1 (en) 2019-11-07
CN112423764A (zh) 2021-02-26
US20240124512A1 (en) 2024-04-18
US20220220147A1 (en) 2022-07-14
US20210047359A1 (en) 2021-02-18
SG11202010790XA (en) 2020-11-27
MX2020011542A (es) 2020-11-24
IL304348A (en) 2023-09-01
AU2019261976A1 (en) 2020-12-03
EP3787635A4 (en) 2022-03-02
US11807658B2 (en) 2023-11-07
KR20210018255A (ko) 2021-02-17
BR112020022068A2 (pt) 2021-04-20

Similar Documents

Publication Publication Date Title
MX2023002507A (es) Inhibidores de cd73.
PH12018502710A1 (en) Heterocyclic compounds as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
NZ788133A (en) Cd73 inhibitors
MX2020013881A (es) Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12018501920B1 (en) Bromodomain inhibitors
PH12019502646A1 (en) Pyrazole magl inhibitors
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
MX2020000135A (es) Nuevos compuestos de quinolinona.
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
IL270927B (en) fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases
EP3868385A4 (en) GASTRIC CANCER TREATMENT COMPOSITION INCLUDING A SYT11 INHIBITOR AS AN ACTIVE INGREDIENT
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
EP3897602A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
TN2021000092A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
EP3820477A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
WO2018211324A8 (en) Prodrugs for the treatment of disease
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения
WO2019157225A3 (en) Certain chemical entities, compositions, and methods
EP3782620A4 (en) PHARMACEUTICAL COMPOSITION WITH A DERIVATIVE COMPOUND OF 1,2-NAPHTHOQUINONE FOR THE PREVENTION OR TREATMENT OF SOLID CANCER OR BLOOD CANCER
WO2019136310A3 (en) Novel compounds for the treatment of neurodegenerative diseases
WO2018067638A3 (en) High mobility group b1 protein inhibitors